Lung & Respiratory Disease Clinical Trials Update: Week 14, 2026

Published April 3, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)

This Phase 3 trial is testing a new add-on treatment called GB-0895 for people aged 12 and older with severe asthma that is not well controlled by current medicines. The treatment is given every six months over a year and aims to reduce the number and severity of asthma attacks. If this treatment works, it could provide a new option for patients struggling with severe asthma symptoms despite existing therapies.

A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma

This Phase 3 study compares a combination treatment called QMF149 with the commonly used medicine budesonide in children aged 6 to under 12 who have asthma. The goal is to see if QMF149 can better control asthma symptoms while being safe for children. Results from this trial could lead to improved treatment choices for young patients and help families manage asthma more effectively.

RSV Vaccination to Reduce Recurrent AECOPD

This Phase 4 trial is testing a vaccine against respiratory syncytial virus (RSV) in adults with chronic obstructive pulmonary disease (COPD) who frequently suffer lung flare-ups. The vaccine aims to prevent infections that trigger these exacerbations, potentially reducing serious lung problems and improving quality of life. The study is taking place in Hong Kong and follows patients for one year to assess long-term benefits.

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma

This Phase 2 trial is investigating the safety and proper dosing of inhaled glycopyrronium bromide in children between 6 and 12 years old with asthma. The study’s findings will help determine if this treatment can safely improve breathing and asthma control for children. This research supports the development of new treatment options tailored specifically for younger patients.

Effect of Low-Dose Versus High-Dose Alpha-Lipoic Acid on Oxidative Stress, Inflammation, and Clinical Outcomes in Acute Exacerbations of Chronic Obstructive Pulmonary Disease

This Phase 3 trial is looking at whether different doses of alpha-lipoic acid, a supplement with antioxidant properties, can help patients recovering from sudden COPD flare-ups. The study hopes to find out if this treatment can reduce lung inflammation and speed up recovery during these difficult episodes. Conducted in Egypt, the trial includes adults aged 40 to 70 who often experience COPD exacerbations.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.